May 3 (Reuters) - Biogen Inc reported a quarterly profit on Tuesday that fell 26% as sales of its blockbuster multiple sclerosis drug Tecfidera continued to be pressured by cheaper versions of the treatment. (Reporting by Leroy Leo in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
213.5 USD | -1.21% | +5.46% | -17.49% |
04-30 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
04-29 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.49% | 31.09B | |
-3.79% | 87.06B | |
+2.76% | 40.25B | |
+55.07% | 24.74B | |
-13.13% | 15.91B | |
-9.12% | 11.96B | |
-15.45% | 11.92B | |
-42.56% | 11.61B | |
+5.24% | 8.73B | |
-4.33% | 8.69B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen quarterly profit falls 26%